Imaging for staging bladder cancer: a clinical study of intravenous ¹¹¹indium‐labelled anti‐MUC1 mucin monoclonal antibody C595

Abstract

This study confirmed the ability of the mAb technique to detect both primary and recurrent invasive bladder tumours and distant metastases. Some lesions shown by mAb imaging were not detected by other methods. The use of mAb imaging has the potential to improve clinical staging and assist in selecting those patients most likely to benefit from radical therapy.

Superparamagnetic iron oxide-C595: Potential MR imaging contrast agents for ovarian cancer detection

“…Also, the use of monoclonal antibody C595, conjugated to a radioisotope, has been used for gamma camera imaging of MUC1-expressing cancers. [1617] Hence, the production and evaluation of magnetic nanoprobe (SPIONs-C595) and its application as an MRI contrast agent for targeted molecular imaging of MUC1-expressing ovarian cancer cells was investigated.…”

Mucins in ovarian cancer diagnosis and therapy

“…The much higher expression of mucins (MUC1, MUC4, MUC5AC, MUC13 and MUC16) in ovarian tumors compared to the surrounding normal tissues can be exploited for the purpose of radioimmunodiagnosis (RID) and radioimmunotherapy (RIT). MUC1 monoclonal antibodies radiolabeled with γ-emitting radioisotopes like 99m TC and 111 In have been successfully used for the radioimmunodiagnosis of various malignancies [82]. As an extension of this technique, monoclonal antibodies to the mucins, radiolabeled with β-emitting isotopes such as 67 Cu, or 188 Re, may be employed for the irradiation of spreading tumor cells (radioimmunotherapy) while sparing normal cells [82-84].…”

“…MUC1 monoclonal antibodies radiolabeled with γ-emitting radioisotopes like 99m TC and 111 In have been successfully used for the radioimmunodiagnosis of various malignancies [82]. As an extension of this technique, monoclonal antibodies to the mucins, radiolabeled with β-emitting isotopes such as 67 Cu, or 188 Re, may be employed for the irradiation of spreading tumor cells (radioimmunotherapy) while sparing normal cells [82-84]. At present, MUC1 and MUC16 are the best and only characterized mucins and monoclonal antibodies against MUC1 and MUC16 are under preclinical and clinical investigations for ovarian cancer treatment (Table 4).…”

Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer

“…Monoclonal antibodies against MUC1 radiolabelled with γ-emitting radioisotopes, such as technetium-99m and indium-111, have been successfully used for the radioimmunological diagnosis of various malignant disease. 56,57 For therapeutic purposes, monoclonal antibodies against the mucins or cancer-specific glycans present on these mucins can be conjugated with radionuclides or cytotoxins (figure 2). Binding of these antibodies or their derived forms to target mucins can induce their internalisation and intracellular retention of the pharmaceuticals or cytotoxins resulting in cytotoxicity.…”